NYSE:EW
Edwards Lifesciences Corp
A premier manufacturer of transcatheter and surgical heart valves with a strong balance sheet and dominant market position in the TAVR sector.
Key Metrics
Investment Thesis
Bull Case
Investors should consider buying this stock due to the company's commanding market leadership in the high-growth TAVR sector and its consistent ability to innovate with next-generation devices. The strong operational cash flow of $1.60B and substantial cash reserves provide flexibility for strategic acquisitions or dividend growth without compromising capital expenditures. Long-term demographic trends regarding aging populations globally will continue to drive structural heart disease prevalence, ensuring sustained demand for Edwards' life-saving products.
Bear Case
Potential buyers should avoid this stock if they are concerned about margin erosion from increasing competition and potential reimbursement cuts in the US healthcare system. The significant drop in net income from $4.17B to $1.07B suggests underlying profitability challenges that may persist if R&D costs remain elevated without immediate commercial return. High levels of goodwill at $1.77B combined with other shareholders' equity deficits could pose balance sheet risks during periods of market stress or asset impairment charges.
About Edwards Lifesciences Corp
Edwards Lifesciences is a global leader in heart valve replacement and repair technologies, serving patients with structural heart disease through its TAVR and SAVR product lines. The company primarily operates in the United States, Europe, Asia-Pacific, Latin America, and Middle East & Africa, focusing on interventional cardiology markets. With over $6 billion in annual revenue, Edwards delivers critical life-saving solutions to hospitals and cardiologists worldwide.
Analysis
Management Discussion
Recent financial performance shows a revenue increase to $6.07B in 2025, driven by strong TAVR demand despite prior year fluctuations. Net income dropped significantly to $1.07B from $4.17B the previous year, likely due to elevated R&D spend of $1.08B and share buybacks of $893.4M impacting cash flow from financing. Cash flow from operations remained robust at $1.60B, providing ample liquidity to fund growth initiatives while maintaining a healthy ending cash balance of $2.94B.
Industry Overview
The medical device industry for structural heart disease is rapidly evolving with transcatheter technologies replacing traditional open-heart surgeries, offering less invasive alternatives to patients. Competition is intensifying as major competitors like Medtronic and Boston Scientific expand their TAVR portfolios, leading to potential pricing pressures. Regulatory scrutiny remains high as agencies monitor long-term outcomes of new devices to ensure patient safety before approval for broader market use.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $5.38B | $6.00B | $5.44B | $6.07B |
| Cost of Revenue | $1.08B | $1.38B | $1.12B | $1.33B |
| Gross Profit | $4.30B | $4.62B | $4.32B | $4.73B |
| Operating Expenses | $2.55B | $3.09B | $2.94B | $3.47B |
| Operating Income | $1.75B | $1.53B | $1.38B | $1.26B |
| R&D | $945.2M | $1.07B | $1.05B | $1.08B |
| G&A | $1.57B | $1.82B | $1.79B | $2.09B |
| Stock-Based Comp | $126.8M | $139.4M | $162.3M | $158.1M |
| D&A | $139.6M | $144.9M | $155.2M | $156.6M |
| Depreciation | $133.9M | $138.9M | $137.6M | $148.2M |
| Amortization | $5.7M | $6.1M | $5.6M | $8.4M |
| Other OpEx | $40.7M | $194.5M | $101.1M | $304.8M |
| Non-Operating Income | $18.9M | $64.0M | $169.4M | $8.7M |
| Interest Expense | $19.2M | $17.6M | — | — |
| Interest Income | $35.5M | $67.2M | $120.3M | $168.8M |
| Pre-Tax Income | $1.77B | $1.60B | $1.55B | $1.27B |
| Income Tax | $245.5M | $198.7M | $152.1M | $216.9M |
| Continuing Ops | $1.52B | $1.40B | $1.40B | $1.06B |
| Discontinued Ops | $0 | $0 | $2.77B | $13.4M |
| Net Income | $1.52B | $1.40B | $4.17B | $1.07B |
| Minority Interest | $0 | $-3.0M | $-4.9M | $-4.1M |
| Net to Common | $1.52B | $1.40B | $4.17B | $1.07B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $3.10B | $4.04B | $6.29B | $6.74B |
| Cash & Equivalents | $769.0M | $1.14B | $3.05B | $2.94B |
| Marketable Securities | $446.3M | $500.5M | $930.7M | $1.29B |
| Accounts Receivable | $643.0M | $775.1M | $609.1M | $659.6M |
| Inventory | $875.5M | $1.17B | $1.09B | $1.13B |
| Other Current Assets | $362.0M | $447.9M | $613.7M | $726.8M |
| Long-Term Assets | $5.20B | $5.33B | $6.77B | $6.96B |
| PP&E (Net) | $1.63B | $1.75B | $1.69B | $1.81B |
| Intangibles | $285.2M | $428.4M | $1.18B | $1.13B |
| Goodwill | $1.16B | $1.25B | $1.78B | $1.77B |
| Operating Leases | $92.3M | $94.0M | $98.2M | $102.7M |
| LT Investments | $1.24B | $583.9M | $307.9M | $278.6M |
| Other LT Assets | $761.7M | $1.18B | $1.69B | $1.83B |
| Total Assets | $8.29B | $9.36B | $13.06B | $13.70B |
| Current Liabilities | $1.02B | $1.20B | $1.51B | $1.81B |
| Accounts Payable | $201.9M | $201.4M | $197.4M | $227.5M |
| Current Leases | $25.5M | $24.9M | $23.4M | $24.5M |
| Taxes Payable | $50.6M | $59.3M | $286.6M | $192.5M |
| Other Current Liab | $744.4M | $909.8M | $997.8M | $1.37B |
| Long-Term Liabilities | $1.46B | $1.45B | $1.49B | $1.55B |
| Long-Term Debt | $596.3M | $597.0M | $597.7M | $598.3M |
| LT Operating Leases | $69.5M | $73.0M | $78.9M | $82.6M |
| Other LT Liab | $797.6M | $778.4M | $810.6M | $865.0M |
| Total Liabilities | $2.49B | $2.64B | $2.99B | $3.36B |
| Shareholders' Equity | $5.81B | $6.72B | $10.06B | $10.34B |
| Retained Earnings | $7.59B | $8.99B | $13.17B | $14.24B |
| AOCI | $-254.9M | $-242.8M | $-244.5M | $-238.3M |
| Total L&E | $8.29B | $9.36B | $13.06B | $13.70B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $1.52B | $1.40B | $4.17B | $1.07B |
| Non-Cash Adjustments | $-932.9M | $-1.55B | $-3.98B | $132.7M |
| Working Capital Changes | $629.2M | $1.05B | $351.5M | $393.1M |
| Cash from Operations | $1.22B | $895.8M | $542.3M | $1.60B |
| Capital Expenditures | $244.6M | $253.0M | $252.4M | $260.2M |
| Cash from Investing | $252.3M | $173.8M | $2.31B | $-712.9M |
| Debt Issuances | $0 | $0 | — | — |
| Share Buybacks | $1.73B | $879.6M | $1.16B | $893.4M |
| Cash from Financing | $-1.58B | $-711.0M | $-983.0M | $-956.8M |
| FX Effect | $19.2M | $16.8M | $38.6M | $-44.8M |
| Net Change in Cash | $-94.8M | $375.4M | $1.91B | $-119.3M |
| Beginning Cash | $867.4M | $772.6M | $1.15B | $3.06B |
| Ending Cash | $772.6M | $1.15B | $3.06B | $2.94B |
Frequently Asked Questions
How does Edwards Lifesciences Corp make money?
The company generates revenue primarily through its Structural Heart business segment, which includes Transcatheter Heart Valve (TAVR) systems like Evolut and SAVR valve systems. Additional revenue streams come from medical device distribution and related accessories that support implantation procedures. The financials reflect a mix of high-margin product sales and significant R&D investments totaling over $1 billion annually to innovate next-generation valve technologies.
What are the main risks for EW?
Intense price competition in the TAVR market could compress margins as new players enter the space and regulatory bodies push for more affordable valve options. Reimbursement policies from government payers like Medicare in the US may shift, potentially reducing reimbursement rates for heart valve procedures. Supply chain disruptions or geopolitical instability could impact the availability of rare earth materials needed for device manufacturing. Regulatory delays or safety concerns regarding new product launches could temporarily halt revenue growth from innovative therapies.
What is EW's competitive advantage?
Edwards holds a dominant market share in the TAVR sector with a robust pipeline of next-generation devices that offer improved safety profiles compared to competitors. The company benefits from an extensive global network of trained heart centers and strong relationships with leading cardiovascular surgeons and cardiologists. Its proprietary manufacturing capabilities and patent portfolio provide a durable moat against emerging generic or lower-cost entrants.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.